**Supplementary Table 5.** Univariate logistic regression analysis for complete end-treatment response and sustained virologic response at 12 weeks after treatment

| Variable                      | P-value | OR   | 95% CI         |
|-------------------------------|---------|------|----------------|
| Age (years)                   | 0.936   | 0.999| 0.968, 1.031   |
| Male sex                      | 0.882   | 1.069| 0.442, 2.584   |
| Body mass index (kg/m²)       | 0.679   | 1.034| 0.883, 1.21    |
| Liver cirrhosis               | 0.077   | 0.445| 0.181, 1.091   |
| IFN-experienced               | 0.997   | Too high | <0.001, –     |
| AST (IU/L)                    |         |      |                |
| Baseline                      | 0.323   | 0.996| 0.99, 1.003    |
| 4 weeks                       | 0.667   | 0.997| 0.983, 1.011   |
| EOT                           | 0.008   | 0.969| 0.946, 0.992   |
| AST >41 IU/L                  |         |      |                |
| Baseline                      | 0.254   | 0.555| 0.201, 1.528   |
| 4 weeks                       | 0.460   | 0.682| 0.247, 1.882   |
| EOT                           | 0.203   | 0.517| 0.187, 1.426   |
| ALT (IU/L)                    |         |      |                |
| Baseline                      | 0.832   | 1.001| 0.994, 1.008   |
| 4 weeks                       | 0.975   | 1.000| 0.985, 1.015   |
| EOT                           | 0.097   | 0.984| 0.965, 1.003   |
| ALT >41 IU/L                  |         |      |                |
| Baseline                      | 0.559   | 1.331| 0.51, 3.47     |
| 4 weeks                       | 0.980   | 0.987| 0.358, 2.722   |
| EOT                           | 0.842   | 0.894| 0.298, 2.681   |
| Bilirubin (mg/dL)             |         |      |                |
| Baseline                      | 0.519   | 0.873| 0.578, 1.319   |
| 4 weeks                       | 0.001   | 0.403| 0.239, 0.68    |
| EOT                           | 0.009   | 0.501| 0.299, 0.84    |
| Bilirubin >2.0 mg/dL          |         |      |                |
| Baseline                      | 0.519   | 0.873| 0.578, 1.319   |
| 4 weeks                       | 0.001   | 0.403| 0.239, 0.68    |
| EOT                           | 0.009   | 0.501| 0.299, 0.84    |
| Albumin (g/dL)                |         |      |                |
| Baseline                      | 0.059   | 2.030| 0.974, 4.23    |
| 4 weeks                       | 0.006   | 3.116| 1.389, 6.993   |
| EOT                           | 0.114   | 1.965| 0.85, 4.544    |
| Albumin <3.5 g/dL             |         |      |                |
| Baseline                      | 0.584   | 0.709| 0.207, 2.427   |
| 4 weeks                       | 0.020   | 0.270| 0.09, 0.813    |
| EOT                           | 0.068   | 0.317| 0.092, 1.087   |
| PT (INR)                      |         |      |                |
| Baseline                      | 0.311   | 0.415| 0.076, 2.279   |
| 4 weeks                       | 0.141   | 0.205| 0.025, 1.691   |
| EOT                           | 0.394   | 0.401| 0.049, 3.277   |
### Supplementary Table 5. Continued

| Variable                              | P-value | OR          | 95% CI               |
|---------------------------------------|---------|-------------|----------------------|
| **Platelet count (/mm$^3$)**          |         |             |                      |
| Baseline                              | 0.015   | 1.009       | 1.002, 1.016         |
| 4 weeks                               | 0.043   | 1.007       | 1.015                |
| EOT                                   | 0.024   | 1.009       | 1.001, 1.016         |
| **Platelet count <150/mm$^3$**        |         |             |                      |
| Baseline                              | 0.173   | 0.527       | 0.21, 1.324          |
| 4 weeks                               | 0.042   | 0.400       | 0.166, 0.969         |
| EOT                                   | 0.083   | 0.453       | 0.185, 1.11          |
| **APRI**                              |         |             |                      |
| Baseline                              | 0.420   | 0.978       | 0.927, 1.032         |
| 4 weeks                               | 0.110   | 0.703       | 0.456, 1.084         |
| EOT                                   | <0.001  | 0.176       | 0.08, 0.387          |
| **APRI >0.7**                         |         |             |                      |
| Baseline                              | 0.228   | 0.576       | 0.235, 1.412         |
| 4 weeks                               | <0.001  | 0.206       | 0.085, 0.499         |
| EOT                                   | 0.005   | 0.255       | 0.098, 0.667         |
| **APRI >1.0**                         |         |             |                      |
| Baseline                              | 0.214   | 0.571       | 0.236, 1.381         |
| 4 weeks                               | 0.001   | 0.185       | 0.067, 0.513         |
| EOT                                   | <0.001  | 0.127       | 0.042, 0.384         |
| **FIB-4**                             |         |             |                      |
| Baseline                              | 0.098   | 0.972       | 0.939, 1.005         |
| 4 weeks                               | 0.017   | 0.831       | 0.714, 0.968         |
| EOT                                   | <0.001  | 0.564       | 0.424, 0.75          |
| **FIB-4 ≥1.45**                       |         |             |                      |
| Baseline                              | 0.270   | 0.565       | 0.205, 1.557         |
| 4 weeks                               | 0.216   | 0.568       | 0.232, 1.391         |
| EOT                                   | 0.061   | 0.415       | 0.165, 1.041         |
| **FIB-4 ≥3.25**                       |         |             |                      |
| Baseline                              | 0.014   | 0.326       | 0.133, 0.801         |
| 4 weeks                               | <0.001  | 0.173       | 0.066, 0.452         |
| EOT                                   | 0.005   | 0.209       | 0.069, 0.631         |
| Baseline HCV RNA (IU/mL)              |         |             |                      |
| >6,000,000 IU/mL                      | 0.361   | 0.623       | 0.226, 1.718         |
| >1,120,000 IU/mL                      | 0.077   | 0.445       | 0.182, 1.091         |
| **LS*, baseline (kPa)**               | <0.001  | 0.947       | 0.921, 0.974         |
| F4 (>12.8 kPa)                        | 0.064   | 0.428       | 0.175, 1.05          |
| F3–F4 (>9.6 kPa)                      | 0.058   | 0.426       | 0.176, 1.029         |
| F2–F4 (>8.4 kPa)                      | 0.226   | 0.575       | 0.235, 1.408         |
| Rapid virologic response              | 0.974   | Too high    | <0.001, –            |

OR, odds ratio; CI, confidence interval; IFN, interferon; AST, aspartate aminotransferase; EOT, end of treatment; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4; HCV, hepatitis C virus; LS, liver stiffness.

*Measured by transient elastography.